Privately-owned Okairos AG of Switzerland has raised €16 million in a Series B financing round to support development of its portfolio of T-cell vaccines against a range of infectious diseases. The round was led by Versant Ventures of the US. ---Subscribe to MedNous to access this article--- Finance, Grants, Deals Company News
